Recombinant Human Galectin-3BP/MAC-2BP Protein, CF

When Recombinant Human Galectin‑3BP/MAC-2BP (Catalog #2226‑GBA) is immobilized at 0.5 µg/mL, 100 μL/well, It binds Recombinant Human Galectin‑3 (Catalog # 1154‑GA) with an ED50 of 0.2‑1 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Galectin-3BP/MAC-2BP Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Galectin-3BP/MAC-2BP is immobilizedat 0.5 µg/mL,100 μL/well, It can bind Recombinant Human Galectin‑3 (Catalog # 1154-GA) with an ED₅₀ of 0.2-1 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived human Galectin-3BP/MAC-2BP protein
  Val19-Asp585, with a C-terminal 10-His tag
• Accession #: Q08380.1
• N-terminal Sequence: Val19
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 65 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 26-30 kDa, 60-69 kDa and 81-94 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS and DTT with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Galectin-3BP/MAC-2BP Protein, CF

• 90K
• Basement membrane autoantigen p105
• BTBD17B
• galectin-3-binding protein
• Galectin3BP
• Galectin-3BP
• L3 antigen
• Lectin galactoside-binding soluble 3-binding protein
• lectin, galactoside-binding, soluble, 3 binding protein
• LGALS3BP
• M2BP
• Mac-2 BP
• Mac-2-binding protein
• MAC2BP
• MAC-2BP
• MAC-2-BP
• serum protein 90K
• Tumor-associated antigen 90K

Background

Galectin-3 binding protein (Galectin-3BP), also known as MAC-2 binding protein (MAC-2BP or M2BP), and the 90 kDa tumor associated antigen (TAA90K or 90K), is a secreted glycoprotein of the scavenger receptor cysteine-rich (SRCR) superfamily (1, 2). Galectin-3BP binds Galectin-3 (formerly MAC-2) with high affinity, but also binds Galectins -1 and -7, several collagen types, fibronectin, beta 1 integrins and nidogen (3, 6, 7). It is widely expressed in all extracellular fluids and in pericellular areas of cell‑rich tissues (1‑3). The 585 amino acid (aa) human Galectin‑3BP contains an 18 aa signal sequence and four definitive domains (4‑6). Domain 1 is a group A scavenger receptor domain (4), domain 2 is a BTB/POZ domain that strongly mediates dimerization (5), and domain 3 is an IVR domain, that is also found following the POZ domain in Drosophila kelch protein. Although little is known about domain 4, recombinant domains 3 and 4 reproduce the solid‑phase adhesion profile of full‑length Galectin‑3BP (5, 6). Glycosylation at seven N‑linked sites, generates a molecular size of 85‑97 kDa (1, 2, 6). Galectin‑3BP dimers form linear and ring‑shaped oligomers, most commonly decamers and dodecamers (3, 5). In vitro, Galectin‑3BP has been shown to stimulate natural killer cells and lymphokine‑activated killer cell activity (2). High Galectin‑3BP expression has been correlated with tumor aggressiveness in several, but not all, study systems (7). Mature human Galectin‑3BP shares 69% aa identity with mouse cyclophilin C‑associated protein (CyCAP), which does not appear to bind Galectin‑3 (8). Human Galectin‑3BP also shares 73%, 67% and 68% aa identity with relatively uncharacterized orthologs in dog, rat and cow, respectively. A human N‑terminally truncated sequence that begins within the BTB/POZ domain (aa 196) has been reported (9).

1. Koths, K. et al. (1993) J. Biol. Chem. 268:14245.
2. Ullrich, A. et al. (1994) J. Biol. Chem. 269:18401.
3. Sasaki, T. et al. (1998) EMBO J. 17:1606.
4. Hohenester, E. et al. (1999) Nat. Struct. Biol. 6:228.
5. Muller, S. A. et al. (1999) J. Mol. Biol. 291:801.
6. Hellstern, S. et al. (2002) J. Biol. Chem. 277:15690.
7. Grassadonia, A. et al. (2004) Glycoconj. J. 19:551.
8. Jalkanen, K. et al. (2001) Eur. J. Immunol. 31:3075.
9. Entrez Accession # EAW89544.

Publications for Galectin-3BP/MAC-2BP/LGALS3BP (2226-GAB)(5)

Publications using 2226-GAB

• Panigrahi, A;Benicky, J;Aljuhani, R;Mukherjee, P;Nováková, Z;Ba?inka, C;Goldman, R; Galectin-3-binding protein inhibits extracellular heparan 6-O-endosulfatse Sulf-2 bioRxiv : the preprint server for biology 2023-12-21 [PMID: 38187586] (Bioassay, Immunoprecipitation, N/A)
• T Seki, M Kanagawa, K Kobayashi, H Kowa, N Yahata, K Maruyama, N Iwata, H Inoue, T Toda Galectin 3-binding protein suppresses amyloid-&amp;beta production by modulating &amp;beta-cleavage of amyloid precursor protein J. Biol. Chem., 2020-01-29;295(11):3678-3691. 2020-01-29 [PMID: 31996371] (Bioassay, Human)
• White M, Roife D, Gomer R Galectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation. J Immunol, 2015-07-01;195(4):1858-67. 2015-07-01 [PMID: 26136428] (Bioassay, Human)
• Silverman A, Nakata R, Shimada H, Sposto R, DeClerck Y A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma. Cancer Res, 2012-03-02;72(9):2228-38. 2012-03-02 [PMID: 22389450] (Bioassay, Human)
• Fukaya Y, Shimada H, Wang LC, Zandi E, DeClerck YA Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J. Biol. Chem., 2008-05-01;283(27):18573-81. 2008-05-01 [PMID: 18450743] (Western Blot)

Bioinformatics

• Uniprot:
  • Q08380.1()